Dr. Meric-Bernstam reviewed advances in phase I breast cancer trial design, highlighting model-assisted dose finding, biomarker integration, and AI-enabled approaches to improve safety, efficiency, and efficacy.

Dr. Seth Wander highlighted biomarker-driven precision medicine, emphasizing liquid biopsies for real-time monitoring, ctDNA as a prognostic marker, and emerging assays to guide personalized breast cancer therapy.

Dr. Cynthia Ma reviewed window-of-opportunity and neoadjuvant trials, highlighting early biomarkers, serial biopsies, and imaging to accelerate drug development and personalize breast cancer treatment.

Panelists emphasized biomarker-driven neoadjuvant trials, ctDNA and MRD as surrogate endpoints, and agile trial designs to accelerate development of therapies for HR-positive, HER2-negative breast cancer.